Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec;16(12):1191-1201.
doi: 10.1080/14760584.2017.1394843. Epub 2017 Oct 30.

Varicella and Herpes Zoster Vaccine Development: Lessons Learned

Affiliations
Free PMC article
Review

Varicella and Herpes Zoster Vaccine Development: Lessons Learned

Charlotte Warren-Gash et al. Expert Rev Vaccines. .
Free PMC article

Abstract

Before vaccination, varicella zoster virus (VZV), which is endemic worldwide, led to almost universal infection. This neurotropic virus persists lifelong by establishing latency in sensory ganglia, where its reactivation is controlled by VZV-specific T-cell immunity. Lifetime risk of VZV reactivation (zoster) is around 30%. Vaccine development was galvanised by the economic and societal burden of VZV, including debilitating zoster complications that largely affect older individuals. Areas covered: We describe the story of development, licensing and implementation of live attenuated vaccines against varicella and zoster. We consider the complex backdrop of VZV virology, pathogenesis and immune responses in the absence of suitable animal models and examine the changing epidemiology of VZV disease. We review the vaccines' efficacy, safety, effectiveness and coverage using evidence from trials, observational studies from large routine health datasets and clinical post-marketing surveillance studies and outline newer developments in subunit and inactivated vaccines. Expert commentary: Safe and effective, varicella and zoster vaccines have already made major inroads into reducing the burden of VZV disease globally. As these live vaccines have the potential to reactivate and cause clinical disease, developing alternatives that do not establish latency is an attractive prospect but will require better understanding of latency mechanisms.

Keywords: Varicella; herpes zoster; live attenuated vaccine; post-marketing surveillance; subunit vaccine; vaccine effectiveness; vaccine efficacy; vaccine safety.

Similar articles

See all similar articles

Cited by 3 articles

References

    1. Schmid DS, Jumaan AO. Impact of varicella vaccine on varicella-zoster virus dynamics. Clin Microbiol Rev. 2010;23(1):202–217. - PMC - PubMed
    1. Arnold N, Messaoudi I. Herpes zoster and the search for an effective vaccine. Clin Exp Immunol. 2017;187(1):82–92. - PMC - PubMed
    1. Steiner I, Kennedy PG, Pachner AR. The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol. 2007;6(11):1015–1028. - PubMed
    1. Cohen JI. The varicella-zoster virus genome. Curr Top Microbiol Immunol. 2010;342:1–14. - PMC - PubMed
    1. Gershon AA, Breuer J, Cohen JI., et al Varicella zoster virus infection. Nat Rev Dis Primers. 2015;1:15016. - PMC - PubMed
    2. • This review gives a useful overview of varicella and zoster epidemiology, pathogenesis, diagnosis, prevention, and treatment.

Publication types

MeSH terms

Feedback